Revolutionary CereVasc® eShunt® System Shows Promise in Treating Intracranial Hypertension The eShunt System exhibits impressive clinical outcomes in treating idiopathic intracranial hypertension, marking a significant advance in neurological care.

Revolutionary CereVasc® eShunt® System Shows Promise in Treating Intracranial Hypertension #United_States #Massachusetts #CereVasc #eShunt #Intracranial_Hypertension

CereVasc, Inc. Publishes Study on eShunt® System for NPH Treatment CereVasc, Inc. reveals promising results from a multi-center study that evaluates the eShunt® System for treating normal pressure hydrocephalus (NPH).

CereVasc, Inc. Publishes Study on eShunt® System for NPH Treatment #USA #Boston #CereVasc #eShunt #NPH_Study

CereVasc's ETCHES Study Enrollment Completion: A New Era in Hydrocephalus Treatment CereVasc has successfully completed the enrollment phase for the groundbreaking ETCHES study, focusing on its eShunt System to treat communicating hydrocephalus, demonstrating promising advances in neurological care.

CereVasc's ETCHES Study Enrollment Completion: A New Era in Hydrocephalus Treatment #United_States #Boston #CereVasc #Hydrocephalus #eShunt_System

CereVasc, Inc. Reaches a Major Milestone with 100th Patient Treated Using the eShunt System CereVasc, Inc. celebrated a significant milestone by treating its 100th patient with the eShunt System, a pioneering approach to hydrocephalus.

CereVasc, Inc. Reaches a Major Milestone with 100th Patient Treated Using the eShunt System #USA #Boston #CereVasc #eShunt #Hydrocephalus

CereVasc's eShunt System Triumphs: Health Canada Approves STRIDE Clinical Trial Authorization CereVasc, Inc. receives critical Investigational Testing Authorization in Canada for their innovative eShunt System targeting normal pressure hydrocephalus, aimed at enhancing patient care.

CereVasc's eShunt System Triumphs: Health Canada Approves STRIDE Clinical Trial Authorization #Canada #Boston #CereVasc #eShunt #STRIDE_Trial

CereVasc's eShunt System Receives FDA Breakthrough Designation for Pediatric Use CereVasc, Inc. has achieved FDA Breakthrough Device Designation for its eShunt® System, advancing treatment for pediatric patients with hydrocephalus.

CereVasc's eShunt System Receives FDA Breakthrough Designation for Pediatric Use #United_States #Pediatric_Care #Boston #CereVasc #eShunt_System

CereVasc Launches Innovative eShunt Clinical Trial for NPH Patients in Argentina CereVasc has received ANMAT approval to begin a clinical trial on the eShunt System to treat elderly patients with Normal Pressure Hydrocephalus in Argentina.

CereVasc Launches Innovative eShunt Clinical Trial for NPH Patients in Argentina #Argentina #Buenos_Aires #CereVasc #eShunt #NPH

CereVasc, Inc.'s eShunt® System Shows Promise in Treating Elderly Patients with Normal Pressure Hydrocephalus CereVasc, Inc. announces promising results from a clinical study of its eShunt® System for treating elderly patients with Normal Pressure Hydrocephalus, showcasing improved patient outcomes.

CereVasc, Inc.'s eShunt® System Shows Promise in Treating Elderly Patients with Normal Pressure Hydrocephalus #United_States #Boston #CereVasc #NPH #eShunt®

CereVasc Launches STRIDE Trial for Innovative eShunt Treatment in NPH Patients CereVasc has begun enrolling patients in the STRIDE clinical trial for the eShunt system, targeting Normal Pressure Hydrocephalus and revolutionary treatment approaches.

CereVasc Launches STRIDE Trial for Innovative eShunt Treatment in NPH Patients #United_States #Massachusetts #CereVasc #eShunt #NPH